Recorded live in Montréal, Canada at ISSCR 2026, Dr. Michael May, President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), and Dr. Janet Rothberg, Senior Director of Process and Analytical Development at CCRM, explore how stem cell discoveries can be translated into commercially viable therapies through scalable manufacturing, company creation, investment, automation, and artificial intelligence. They emphasize the importance of considering manufacturing, quality control, market selection, reimbursement, and the evolving standard of care much earlier in the cell therapy development process. They also share their vision for a future in which robust bioprocessing, better use of data, and improved regulatory and reimbursement models make induced pluripotent stem cell (iPSC)-derived therapies more affordable and widely accessible.

Find more episodes at stemcellpodcast.com or wherever you get your podcasts.